Evidence map›Paper›PMID 41482542›Full record

ArticleNature biotechnology2026

Predicting small molecule-RNA interactions without RNA tertiary structures.

Yuhan Fei, Pengfei Wang, Jiasheng Zhang, Xinyue Shan, Zilin Cai, Jianbo Ma, Yangming Wang, Qiangfeng Cliff Zhang

Abstract read
PubMed Publisher
In one paragraph

Article in Nature biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Machine Learning for RNA-Targeting Drug Design.Journal of chemical information and modeling · 2026
    Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yuhan Fei *State Key Laboratory of Membrane Biology, Tsinghua University, Beijing, China.ORCID http://orcid.org/0000-0002-7458-8180
Pengfei Wang *State Key Laboratory of Membrane Biology, Tsinghua University, Beijing, China.
Jiasheng Zhang *State Key Laboratory of Membrane Biology, Tsinghua University, Beijing, China.
Xinyue ShanState Key Laboratory of Membrane Biology, Tsinghua University, Beijing, China.
Zilin CaiState Key Laboratory of Membrane Biology, Tsinghua University, Beijing, China.
Jianbo MaState Key Laboratory of Membrane Biology, Tsinghua University, Beijing, China.
Yangming WangInstitute of Molecular Medicine, College of Future Technology, Peking University, Beijing, China. yangming.wang@pku.edu.cn.ORCID http://orcid.org/0000-0001-6974-6060
Qiangfeng Cliff ZhangState Key Laboratory of Membrane Biology, Tsinghua University, Beijing, China. qczhang@tsinghua.edu.cn.ORCID http://orcid.org/0000-0002-4913-0338

Funding

National Natural Science Foundation of China (National Science Foundation of China) 32025007National Natural Science Foundation of China (National Science Foundation of China) 32100504National Natural Science Foundation of China (National Science Foundation of China) 32125007National Natural Science Foundation of China (National Science Foundation of China) 32130017National Natural Science Foundation of China (National Science Foundation of China) 32230018
6 · The paper itself

Abstract

Small molecules can bind RNAs to regulate their fate and functions, providing promising opportunities for treating human diseases. However, current tools for predicting small molecule-RNA interactions (SRIs) require prior knowledge of RNA tertiary structures. Here we present SMRTnet, a deep learning method that uses multimodal data fusion to integrate two large language models with convolutional and graph attention networks to predict SRIs on the basis of RNA secondary structure. SMRTnet achieves high performance across multiple experimental benchmarks, substantially outperforming existing tools. SMRTnet predictions for ten disease-associated RNA targets identified 40 hits of RNA-targeting small molecules with nanomolar-to-micromolar dissociation constants. Focusing on the MYC internal ribosome entry site, SMRTnet-predicted small molecules showed binding scores correlated closely with observed validation rates. One predicted small molecule downregulated MYC expression, inhibited proliferation and promoted apoptosis in three cancer cell lines. Thus, by eliminating the need for RNA tertiary structures, SMRTnet expands the scope of feasible RNA targets and accelerates the discovery of RNA-targeting therapeutics.

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.